Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 September 1995 | Volume 123 Issue 5 | Pages 368-382
Objective: To review the basic virology of human papillomavirus (HPV) and the natural history of HPV infection and to discuss current and potential therapies.
Data Sources: The MEDLINE database (1966 to 1994) was searched to identify English-language articles and abstracts on HPV biology and antiviral chemotherapy.
Study Selection: Peer-reviewed basic science and clinical research studies on the molecular, cellular, and human biology of HPV infection.
Data Extraction: Summaries of data from research studies on the biology of papillomavirus infection and information from review articles on the basic and applied pharmacology of antiviral agents.
Data Synthesis: Papillomavirus infections are very common. Human papillomavirus infections may be asymptomatic or may be manifested in various benign or malignant lesions, most notably anogenital condyloma and anogenital carcinoma. Currently, therapeutic options for HPV infection are limited, expensive, and often ineffective. By understanding the basic virology and natural history of HPV infection, potential sites for pharmacologic intervention can be identified. Although currently available antiviral compounds are inactive against HPV, they serve as models for the rational design of HPV antiviral drugs.
Conclusions: Although HPV infection causes substantial morbidity and expense, uniformly effective therapy for HPV infection is not currently available. Several processes in the HPV infection cycle are appropriate targets for the development of antiviral agents. The development of compounds active against HPV could prevent the benign and malignant diseases associated with HPV infection.
Author and Article Information
From Burroughs Wellcome Co., Research Triangle Park, North Carolina, and Duke University Medical Center, Durham, North Carolina.
REVIEW
Antiviral Therapy for Human Papillomaviruses: Rationale and Prospects
![]()
Acknowledgments: The authors thank Peter Howley, Karl M&129;nger, Lynn Smiley, and John Reardon for their helpful discussion and critical review.
Requests for Reprints: William C. Phelps, MD, Division of Virology, RC2, Burroughs Wellcome Co., 3030 Cornwallis Road, PO Box 12700, Research Triangle Park, NC 27709-2700.
Current Author Addresses: Dr. Phelps: Division of Virology, RC2, Burroughs Wellcome Co., 3030 Cornwallis Road, PO Box 12700, Research Triangle Park, NC 27709-2700.
This article has been cited by other articles:
![]() |
D. Opalka, C. E. Lachman, S. A. MacMullen, K. U. Jansen, J. F. Smith, N. Chirmule, and M. T. Esser Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay Clin. Vaccine Immunol., January 1, 2003; 10(1): 108 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. R. Hengge, M. Goos, and R. Arndt Topical Treatment of Warts and Mollusca with Imiquimod Ann Intern Med, January 4, 2000; 132(1): 95 - 95. [Full Text] [PDF] |
||||
![]() |
W. I. White, S. D. Wilson, W. Bonnez, R. C. Rose, S. Koenig, and J. A. Suzich In Vitro Infection and Type-Restricted Antibody-Mediated Neutralization of Authentic Human Papillomavirus Type 16 J. Virol., February 1, 1998; 72(2): 959 - 964. [Abstract] [Full Text] [PDF] |
||||